Vericel (VCEL) Short-term Investments (2018 - 2026)
Vericel (VCEL) posted Short-term Investments of $37.1 million for Q2 2026, up 2.93% sequentially from $36.0 million in Q1 2026, and up 2.07% YoY from $36.3 million in Q2 2025.
Vericel (VCEL) Short-term Investments (2018 - 2026) Analysis & Trends
Vericel has reported Short-term Investments for 9 years, with the latest figure at $37.1 million in Q2 2026.
- Quarterly Short-term Investments rose 2.07% year-over-year to $37.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.1 million (up 2.07% YoY) and the FY2025 annual result came in at $37.4 million, down 10.28% from the prior year.
- Short-term Investments improved to $37.1 million in Q2 2026 per VCEL's latest filing, from $36.0 million in the prior quarter.
- Over five years, Short-term Investments peaked at $68.5 million in Q4 2022 and troughed at $35.0 million in Q3 2025.
- A 5-year average of $45.1 million and a median of $44.8 million in 2022 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2022 and 2023: Short-term Investments jumped 95.25% in 2022, then tumbled 40.9% in 2023.
- Over 5 years, Short-term Investments stood at $68.5 million in 2022, then sank by 40.9% to $40.5 million in 2023, then increased by 3.02% to $41.7 million in 2024, then dropped by 10.28% to $37.4 million in 2025, then retreated by 0.82% to $37.1 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $37.1 million, $36.0 million, and $37.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.10 Mn |
| Mar 31, 2026 | 36.05 Mn |
| Dec 31, 2025 | 37.41 Mn |
| Sep 30, 2025 | 34.98 Mn |
| Jun 30, 2025 | 36.35 Mn |
| Mar 31, 2025 | 39.41 Mn |
| Dec 31, 2024 | 10.53 Mn |
| Sep 30, 2024 | 16.67 Mn |
| Jun 30, 2024 | 25.56 Mn |
| Mar 31, 2024 | 47.71 Mn |
| Dec 31, 2023 | 17.78 Mn |
| Sep 30, 2023 | 23.09 Mn |
| Jun 30, 2023 | 54.81 Mn |
| Mar 31, 2023 | 57.44 Mn |
| Dec 31, 2022 | 68.47 Mn |
| Sep 30, 2022 | 45.72 Mn |
| Jun 30, 2022 | 44.64 Mn |
| Mar 31, 2022 | 44.89 Mn |
| Dec 31, 2021 | 35.07 Mn |
| Sep 30, 2021 | 43.74 Mn |